Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study-Reference-Cited by-同舟云学术

Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study

Published:2022-06 Issue:6 Volume:9 Page:e434-e444
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Pemmaraju Naveen,Garcia Jacqueline S,Potluri Jalaja,Harb Jason G,Sun Yan,Jung Paul,Qin Qin Q,Tantravahi Srinivas K,Verstovsek Srdan,Harrison Claire

Funder

AbbVie

Publisher

Elsevier BV

Subject

Hematology

Reference35 articles.

1. Myelofibrosis: clinicopathologic features, prognosis, and management;O'Sullivan;Clin Adv Hematol Oncol,2018

2. Myelofibrosis in 2019: moving beyond JAK2 inhibition;Schieber;Blood Cancer J,2019

3. The genetic basis of primary myelofibrosis and its clinical relevance;Rumi;Int J Mol Sci,2020

4. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management;Tefferi;Am J Hematol,2018

5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med,2012

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and Predictive Models in Myelofibrosis;Current Hematologic Malignancy Reports;2024-08-24

2. APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy;Cell Death & Disease;2024-06-18

3. Recent advances in JAK2 inhibition for the treatment of myelofibrosis;Expert Opinion on Pharmacotherapy;2024-06-12

4. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature;British Journal of Haematology;2024-06-10

5. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?;Expert Opinion on Pharmacotherapy;2024-04-12